Japan will provide public health insurance coverage for Amshapri, the world's first practical iPS cell-derived treatment for Parkinson's disease [1, 2, 3].
This approval marks a global milestone in regenerative medicine. By transplanting cells derived from induced pluripotent stem cells (iPS cells) into the brain, the treatment aims to improve motor functions for patients who have exhausted other options [1, 3].
The Central Social Insurance Medical Council, an advisory body to the Ministry of Health, Labour and Welfare, approved the insurance application on Wednesday [1, 2]. Coverage is scheduled to begin on May 20 [2]. Sumitomo Pharma previously obtained manufacturing and sales approval for the drug in March 2026, with the approval remaining valid for seven years [3].
The cost of the treatment is set at 55,307,673 yen per patient [2]. While the high price point ensures patient access through the public system, it presents a financial challenge for the manufacturer.
"I am happy about the insurance coverage, but I am also bracing myself," Sumitomo Pharma President Toru Kimura said. "With the price at 55.3 million yen, it is clearly in the red under the current cost structure, but I want to make it a form where we can recover the investment by further promoting mechanization" [1].
Medical experts suggest the therapy could significantly improve the quality of life for those suffering from the degenerative disorder [3]. The rollout will be available nationwide across Japan's public medical insurance system [2].
“iPS cell-derived regenerative medicine is expected to be put into practical use for the first time in the world.”
The integration of iPS cell therapy into a national insurance framework transitions a theoretical scientific breakthrough into a scalable medical reality. While the high cost per dose creates an immediate deficit for Sumitomo Pharma, the government's willingness to subsidize the treatment signals a strategic commitment to leading the global regenerative medicine market. The success of Amshapri will likely serve as the regulatory and financial blueprint for future stem-cell treatments targeting other neurological conditions.
